Fusions of antibodies to CD38 and attenuated interferon alpha
US9611322B2 · kind B2 · utility
5Cited by
8References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2014 |
| Grant date | Apr 4, 2017 |
| Priority date | — |
| Expiry date | Apr 28, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.